Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Ruxolitinib is a selective JAK1/2 inhibitor that is widely used for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera (PV). Despite its clinical efficacy for MPNs, ruxolitinib possesses immunosuppressive properties that potentially increase the risks...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Infect Drug Resist
Main Authors: Sakiyama, Emiko, Chinen, Yoshiaki, Tsukamoto, Taku, Takimoto-Shimomura, Tomoko, Kuwahara-Ota, Saeko, Matsumura-Kimoto, Yayoi, Shimura, Yuji, Kobayashi, Tsutomu, Horiike, Shigeo, Kuroda, Junya
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7152536/
https://ncbi.nlm.nih.gov/pubmed/32308443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S249030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados